<DOC>
	<DOC>NCT01116271</DOC>
	<brief_summary>The purpose of this study is to determine whether treatment with Selumetinib (AZD6244) (Hyd-Sulfate) in combination with Irinotecan as a second treatment in patients with K-ras or B-raf mutation will prevent tumor progression and prolong progression free survival.</brief_summary>
	<brief_title>Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec</brief_title>
	<detailed_description>A Dose Finding and Phase II Study of Selumetinib (AZD6244) (Hyd-Sulfate) in Combination with Irinotecan, in 2nd Line Patients with K-ras or B-raf Mutation Positive Advanced or Metastatic Colorectal Cancer</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histological or cytological confirmation of advanced or metastatic colorectal cancer with available tissue and tumor sample confirmed as Kras or Braf mutation positive. Current failure of 1st line anticancer therapy with an oxaliplatin and bevacizumab based regimen or patients relapsing within 12 months of completing adjuvant FOLFOX . Treatment within 14 days prior to first study treatment with conventional therapy or treatment within 28 days prior to first study treatment with an investigational drug Prior treatment with a MEK or Braf inhibitor or any irinotecancontaining regimen Prior treatment with a MEK or Braf inhibitor or any irinotecancontaining regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>colorectal</keyword>
	<keyword>second line therapy</keyword>
	<keyword>K-ras or B-raf mutations</keyword>
	<keyword>response rate</keyword>
	<keyword>Progression Free Survival</keyword>
</DOC>